Cargando…

Super-enhancer acquisition drives oncogene expression in triple negative breast cancer

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease lacking known molecular drivers and effective targeted therapies. Cytotoxic chemotherapy remains the mainstay of treatment for TNBCs, which have significantly poorer survival rates compared to other breast cancer subtypes. In addition t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raisner, Ryan, Bainer, Russell, Haverty, Peter M., Benedetti, Kelli L., Gascoigne, Karen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316302/ https://www.ncbi.nlm.nih.gov/pubmed/32584896 http://dx.doi.org/10.1371/journal.pone.0235343

Ejemplares similares

Super-enhanced MARCO variant drives triple-negative breast cancer progression
por: Lin, Weei-Chin, et al.
Publicado: (2022)

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Huang, Hao, et al.
Publicado: (2021)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

The Modeling of Super Deep Learning Aiming at Knowledge Acquisition in Automatic Driving
por: Liang, Yin, et al.
Publicado: (2022)

Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses
por: Xiao, Xiao, et al.
Publicado: (2021)

An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer
por: Dardis, Gabrielle J., et al.
Publicado: (2023)

Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
por: Zurlo, Giada, et al.
Publicado: (2019)

Super enhancer-driven core transcriptional regulatory circuitry crosstalk with cancer plasticity and patient mortality in triple-negative breast cancer
por: Shi, Wensheng, et al.
Publicado: (2023)

The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer
por: Yang, Xue, et al.
Publicado: (2023)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
por: Morrison, Chevaun D, et al.
Publicado: (2017)

Mesenchymal Cells Support the Oncogenicity and Therapeutic Response of the Hedgehog Pathway in Triple-Negative Breast Cancer
por: Reyes-Ramos, Ana M., et al.
Publicado: (2019)

SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021)

Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1
por: Ren, Yi, et al.
Publicado: (2020)

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer
por: Fang, Wentong, et al.
Publicado: (2021)

The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer
por: Wang, Wei, et al.
Publicado: (2023)

Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma
por: Li, Lin, et al.
Publicado: (2021)

Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
por: Jia, Qunying, et al.
Publicado: (2020)

HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression
por: Warburton, Alix, et al.
Publicado: (2018)

PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
por: Byerly, Jessica, et al.
Publicado: (2016)

MicroRNA-454 may function as an oncogene via targeting AKT in triple negative breast cancer
por: Li, Qun, et al.
Publicado: (2017)

Irradiated Triple-Negative Breast Cancer Co-Culture Produces a Less Oncogenic Extracellular Matrix
por: Brett, Elizabeth, et al.
Publicado: (2022)

The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
por: Li, Yao, et al.
Publicado: (2023)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Activation of Oncogenic Super-Enhancers Is Coupled with DNA Repair by RAD51
por: Hazan, Idit, et al.
Publicado: (2019)

WNT-mediated gene gating: a novel principle connecting oncogenic super-enhancers with the nuclear pore to drive pathological expression of MYC
por: Göndör, Anita
Publicado: (2020)

Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer
por: Janic, Branislava, et al.
Publicado: (2021)

Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro
por: Garza-Morales, Rodolfo, et al.
Publicado: (2018)

DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
por: Ogbu, Stella C., et al.
Publicado: (2021)

Glycolytic Metabolic Remodeling by the Truncate of Glioma-Associated Oncogene Homolog 1 in Triple-Negative Breast Cancer Cells
por: Lee, Su Hyun, et al.
Publicado: (2022)

LEM Domain Containing 1 Acts as a Novel Oncogene and Therapeutic Target for Triple-Negative Breast Cancer
por: Li, Xiangling, et al.
Publicado: (2023)

Trigger and Data Acquisition for the Super LHC
por: Smith, Wesley H
Publicado: (2004)

Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes
por: Dooley, Katharine E., et al.
Publicado: (2016)

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells
por: Bhat, Kruttika, et al.
Publicado: (2017)

Nuclear ErbB-2-Induced Transcriptome Drives Triple Negative Breast Cancer Growth
por: Chervo, Maria F, et al.
Publicado: (2021)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects
por: Loupe, Jacob M., et al.
Publicado: (2016)

Somatic LINE-1 promoter acquisition drives oncogenic FOXR2 activation in pediatric brain tumor
por: Flasch, Diane A., et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hoej122951mjj0vlhjqndmq395